<DOC>
	<DOCNO>NCT00216502</DOCNO>
	<brief_summary>The purpose study evaluate long-term efficacy safety galantamine patient Alzheimer 's disease .</brief_summary>
	<brief_title>A Study Safety Effectiveness Galantamine Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Dementia chronic , progressive brain disease may involve number symptom , include memory loss change personality , behavior , judgment , attention span , language thought . The common type dementia Alzheimer 's disease . Over time , patient Alzheimer 's disease may lose ability perform daily task relate personal care ( example bathing , dress , eat ) may unable handle money travel familiar place . Previous short-term study show galantamine safe effective treating patient Alzheimer 's disease , however long-term safety effectiveness galantamine examine . This multicenter , randomize study ass whether long-term treatment galantamine delay onset symptom associate Alzheimer 's disease examine safety effectiveness long-term treatment galantamine . Patients receive 12 month open-label treatment galantamine , follow 24 month double-blind treatment galantamine placebo . Safety evaluation ( incidence adverse event , physical examination , 12 lead ECGs , vital sign , laboratory test ) perform throughout study . Effectiveness determine use standard test rating scale ass mental status , functioning , think , behavior , judgment language ( Mini Mental Status Exam [ MMSE ] , Alzheimer 's Disease Assessment Scale [ ADAS-cog ] ; Disability Assessment Dementia [ DAD ] , Clinician 's Interview Based Impression Changes plus Family Input [ CIBIC-plus ] ) . After first 4 week , assessment perform every 3 month open-label phase ( first 12 month ) every 6 month double-blind phase ( 13-36 month ) . Patients whose symptom worsen defined increase &gt; = 4 point ADAS-cog score start double-blind phase withdrawn study . The study hypothesis long-term treatment galantamine effective delay cognitive deterioration patient Alzheimer 's disease galantamine well-tolerated long term treatment . Galantamine 4 milligram twice daily mouth 4 week , 8 milligram twice daily 48 week . Thereafter , galantamine give 8 milligram twice daily additional 24 month .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Diagnosis probable Alzheimer 's disease accord accept medical standard Patients mild moderate impairment thinking , reason , judgment define score 1124 Mini Mental Status Exam ( MMSE , standard assessment tool Alzheimer 's disease ) Female patient must postmenopausal Patients caregiver must sign informed consent form Exclusion Criteria : Patients diagnosis Parkinson 's Disease , Pick 's Disease , Huntington 's Chorea , CreutzfeldJacob disease , Down 's syndrome , brain cancer , mental retardation , epilepsy , psychiatric disease , liver , kidney heart failure , significant heart , lung , digestive , hormone mental disease Vitamin B deficiency Patients previous severe head injury blood clot brain Patients hospitalize , live nursing home residential care facility Patients brain infection abscess , meningitis , encephalitis Patients history drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>galantamine</keyword>
	<keyword>placebo</keyword>
	<keyword>Caregiver</keyword>
	<keyword>Brain disease</keyword>
	<keyword>Memory loss</keyword>
</DOC>